Enlightenment of American MTM model to the construction of pharmaceutical service capability in primary medical institutions in ChinaZHAO Wen-min, YANG Yi, TIAN Kan1292-1296
Discussion on cell therapy regulatory policy of China, USA and EUWANG Qing-qing, WANG Chong, HUANG Zhi-hong1297-1302
Pharmacological and clinical evaluation of elagolix in the treatment of endometriosisLI Chun-xing, LIU Hua1303-1306
Case analysis of organic impurities analysis and control in chemical genericsZHANG Jun-lin, HE Wu1307-1311
Study the hepatotoxicity of monoanthranone with emodin-type using in vitro 3D liver modelDAN Mo, LIU Dong, HUANG Shu-jia, WANG Yu, WANG Qi, ZHAO Yan-yan1312-1317
Evaluation of pharmacokinetics and pharmacodynamic indicators of octreotide acetate sustained release microspheres in ratsWANG Lei, SHA Chun-jie, YU Fei, LENG Guang-yi, SHAO Xin, YANG Hui-jie, LIU Fang-jie, LIU Wan-hui1318-1324
PDZ domains can serve as a target for developing new drugsZHU Zhi-ying, QIN Ya-juan, LI Ting-you1325-1329
Progress in numerical simulation technology for fluidized bed granulationZENG Jia, HUANG Ting, FENG Ling-lin, XUE Man, CHEN Jian-xing, DU Ruo-fei, FENG Yi1330-1342